Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
J Cutan Pathol. 2013 Oct;40(10):884-6. doi: 10.1111/cup.12199. Epub 2013 Aug 7.

Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma.

Author information

  • 1Department of Pathology, NorthShore University HealthSystem, Evanston, IL, USA,; University of Chicago Pritzker School of Medicine, Chicago, IL, USA.


BRAF inhibition therapy, used to treat melanomas with BRAF mutations, is associated with both neoplastic and non-neoplastic cutaneous side effects including squamous cell carcinomas, warty dyskeratomas, verrucous keratoses, photosensitivity and widespread eruptions that present histopathologically as acantholytic dyskeratosis. We report a case of a patient undergoing BRAF inhibition therapy for disseminated melanoma with a V600E mutation who developed bilateral areolar leiomyomas, one of which was biopsied and the other of which resolved after discontinuation of vemurafenib therapy. To our knowledge, this is the first reported case of a mesenchymal neoplasm developing in association with BRAF inhibition therapy.

© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


Braf; cutaneous neoplasm; leiomyoma; malignant melanoma

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk